H.C. Wainwright lowered the firm’s price target on Adaptimmune (ADAP) to $3.50 from $4 and keeps a Buy rating on the shares following the Q3 report.
H.C. Wainwright lowered the firm’s price target on Adaptimmune (ADAP) to $3.50 from $4 and keeps a Buy rating on the shares following the Q3 report.